



Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

July 8, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210708005048/en/): <https://www.businesswire.com/news/home/20210708005048/en/>

Investor Contact

Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media Contact

Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

Source: Sage Therapeutics, Inc.